First trimester screening and progesterone levels in HIV positive women under HAART therapy

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Objectives: HIV (Human Immunodeficiency Virus) that ultimately determines the development of AIDS evolved in time in a pandemic disease. Our study evaluated first trimester markers for aneuploidy, serum progesterone levels in first and second trimester in HIV positive pregnant women under HAART therapy. Material and methods: It was a prospective study that took place between January 2017- December 2019 in "Cuza-Vodă" Hospital from Romania. We analysed first trimester PAPP-A, βHCG, first and second trimester progesterone of 25 HIV positive pregnant women under HAART therapy and compared them with seronegative pregnant women. Results: Both βHCG and first and second trimester progesterone were lower in HIV positive women under HAART therapy. These alterations of first trimester markers for aneuploidy might lead to an over estimation of the risk for Down syndrome. Conclusions: Obstetricians need to know the alterations of first trimester markers for aneuploidy so they can correctly advise these women accordingly.

Cite

CITATION STYLE

APA

Iasi, U. A., Alexandra, T. M., Mircea, O., Alexandru, L., Roxana, M. D., & Dragos, N. (2022). First trimester screening and progesterone levels in HIV positive women under HAART therapy. Ginekologia Polska, 93(3), 224–228. https://doi.org/10.5603/GP.a2021.0096

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free